References
- Smith MA , ZhuX, TabatonMet al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 19(1), 363–372 (2010).
- Liu G , MenP, PerryG, SmithMA. Nanoparticle iron chelator conjugates as multifunctional disease-modifying drugs for prevention and treatment of Alzheimer‘s disease. In: Nanomedicine and the Nervous System. Martin CR, Preedy VR, Hunter RJ (Eds). Science Publisher, Inc., Enfield, NH, USA, 347–366 (2012).
- Bonda DJ , LiuG, MenP, PerryG, ZhuX, SmithMA. Nanoparticle delivery of transition-metal chelators to the brain: oxidative stress will never see it coming! CNS Neurol. Disord. Drug Targets11(1), 81–85 (2012).
- Liu G , GarrettMR, MenP, ZhuX, PerryG, SmithMA. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta1741(3), 246–252 (2005).
- Halliwell B , GutteridgeJMC. Free Radicals in Biology and Medicine. Oxford University Press, New York, NY, USA (1999).
- Li X , JankovicJ, LeW. Iron chelation and neuroprotection in neurodegenerative diseases. J. Neural Transm.118(3), 473–477 (2011).
- Stankiewicz JM , BrassSD. Role of iron in neurotoxicity: a cause for concern in the elderly? Curr. Opin. Clin. Nutr. Metab. Care12(1), 22–29 (2009).
- Kupershmidt L , WeinrebO, AmitT, MandelS, Bar-AmO, YoudimMB. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience189(25), 345–358 (2011).
- Weinreb O , MandelS, Bar-AmO, AmitT. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer‘s disease: a tribute to Moussa Youdim. J. Neural Transm.118(3), 479–492 (2011).
- Storr T , ScottLE, BowenMLet al. Glycosylated tetrahydrosalens as multifunctional molecules for Alzheimer‘s therapy. Dalton Trans. 16(28), 3034–3043 (2009).
- Liu G , MenP, KudoW, PerryG, SmithMA. Nanoparticle-chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neuroscience Lett.455(3), 187–190 (2009).
- Crapper McLachlan DR , DaltonAJ, KruckTPet al. Intramuscular desferrioxamine in patients with Alzheimer‘s disease. Lancet 337(8753), 1304–1308 (1991).
- Regland B , LehmannW, AbediniIet al. Treatment of Alzheimer‘s disease with clioquinol. Dement. Geriatr. Cogn. Disord. 12(6), 408–414 (2001).
- Ritchie CW , BushAI, MackinnonAet al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase II clinical trial. Arch. Neurol. 60(12), 1685–1691 (2003).
- Casdorph HR . EDTA chelation therapy: efficacy in brain disorders. In: A Textbook on EDTA Chelation Therapy. Cranton EM (Ed.). Hampton Roads Publishing Company, Inc., Charlottesville, VA, USA, 142–163 (2001).
- Kreuter J . Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev.47(1), 65–81 (2001).
- Wilson B , SamantaMK, SanthiK, KumarKP, ParamakrishnanN, SureshB. Poly(N-butylcyanoacrylate)nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer‘s disease. Brain Res.1200(20), 159–168 (2008).
- Liu G , MenP, HarrisPL, RolstonRK, PerryG, SmithMA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett.406(3), 189–193 (2006).